In CLL muated/unmutated is beginning to matter in treatment choice.. but what about the other large component ...sex??
Surely in the fledgling era of personalised medicine this should be looked at?
A recent study look at this in DLBCL, think Richter's, and the use of rituxan a component in RCHOP, indicates that a higher dose in men was of great benefit...
As the study states
We conclude that the higher rituximab dose for elderly male patients abrogated the adverse prognosis of male sex without increasing toxicity. In the era of personalized medicine, sex-specific pharmacokinetics and toxicities should be investigated for all drugs where these parameters impact on outcome.
Slightly off topic. It is the intention of the NHS in England in 2019 to ask all medics to ask patients their gender to go on their medical records. This will include gay, transsexual etc etc. It will be compulsory for a medic to ask. Why? Who knows?
Is treatment dose based on height and weight/ BMI? Have any trials treated the different sexes with different doses?
There is supposed to be a higher percentage of males with CLL so this could affect results and resultant outcomes.
If treatment is based on male dosage are females being overdosed?
Interesting! I've seen somewhere that doses of general medicines are - or were - measured by how much an average male needed, rather than how much a female required. I don't know if this is still in force.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.